Patent ID: 8492383
Filing Date: 2013-07-23
Classification: A61K,A61P

Abstract:
1. A pharmaceutical combination for simultaneous, separate or sequential use for the treatment of patients with chronic lymphocytic leukemia which comprises (a) chlorambucil- and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide having the following formula in which the active ingredients (a) and (b) are each present in free form or in the form of a pharmaceutically acceptable salt and wherein (a) chlorambucil is in a dose amount of 0.2 to 0.8 mg/kg of body weight/day and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in a dose amount of 50 mg to 800 mg per day.